Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone914-347-4300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$588.29 million
Profitability
Miscellaneous
Employees484
OptionableOptionable
Acorda Therapeutics (NASDAQ:ACOR) Frequently Asked Questions
What is Acorda Therapeutics' stock symbol?
Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."
How were Acorda Therapeutics' earnings last quarter?
Acorda Therapeutics Inc (NASDAQ:ACOR) released its quarterly earnings data on Wednesday, October, 31st. The biopharmaceutical company reported $0.17 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.15. The biopharmaceutical company earned $142.80 million during the quarter, compared to analysts' expectations of $82.74 million. Acorda Therapeutics had a negative net margin of 24.88% and a positive return on equity of 13.72%. The firm's revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.43 earnings per share. View Acorda Therapeutics' Earnings History.
When is Acorda Therapeutics' next earnings date?
What price target have analysts set for ACOR?
10 equities research analysts have issued twelve-month price targets for Acorda Therapeutics' stock. Their forecasts range from $10.00 to $37.00. On average, they expect Acorda Therapeutics' stock price to reach $24.3333 in the next twelve months. This suggests a possible upside of 49.7% from the stock's current price. View Analyst Price Targets for Acorda Therapeutics.
What is the consensus analysts' recommendation for Acorda Therapeutics?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acorda Therapeutics in the last year. There are currently 2 sell ratings, 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Acorda Therapeutics.
What are Wall Street analysts saying about Acorda Therapeutics stock?
Here are some recent quotes from research analysts about Acorda Therapeutics stock:
- 1. JPMorgan Chase & Co. analysts commented, "Friday, HSGX disclosed that discussions with the FDA had informally concluded ultimately resulting in the suspension of NeoCart’s development. The FDA notified HSGX that the company would be required to run an additional clinical trial to submit the BLA for NeoCart. Given HSGX’s capital position, this is not feasible and HSGX decided to suspend NeoCart development. To that end, HSGX will now explore all strategic options. HSGX’s outcome creates a few takeaways, in our view, regarding the cartilage segment which we discuss below." (12/26/2018)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks, and uncertainties. We currently ascribe $570M to AMPYRA and $850M to INBRIJA on a risk-adjusted net present value (rNPV) basis, using an 85% probability of success and a 15% discount rate for INBRIJA along with a 12% discount rate for AMPYRA." (11/5/2018)
- 3. Jefferies Financial Group Inc analysts commented, "Q3 beat due to delayed launch of generic Amprya last qtr…however, IMS points to -40% Q3 reduction in TRx already and as expected. Key milestone for ACOR is potential approval of 5th PDUFA. Analysis below suggests probability of approval is incrementally higher given recent developments – but we are Hold due to fairly balanced risk/reward up and down on the scenarios. With Ampyra generic happening now as expected, focus shifts to approval of Inbrija and whether ACOR should remain a standalone or look to sell itself to maximize value. When asked on the call, mgmt. says they are regularly exploring all options to maximize shareholder value (though if they do an OUS partnership as guided we predict stock would go down based on less M&A likelihood)." (11/4/2018)
- 4. Cantor Fitzgerald analysts commented, ": We are reiterating our Neutral rating and $32 PT for ACOR. The company announced today that the US Court of Appeals has upheld a decision to invalidate four Ampyra patents, with the last remaining patent having expired on July 30, 2018. However, in our recent initiation on ACOR, we did not ascribe value to Ampyra due to the prior court rulings, which we predicted would be upheld on appeal. We anticipate a steep decline in Ampyra sales as generics now have an opportunity to enter the market, and this court decision may prompt generics to launch soon." (9/10/2018)
- 5. According to Zacks Investment Research, "Acorda is presently working on strengthening its Parkinson’s pipeline by focusing on the late stage candidate Inbrija in its portfolio. Inbrija’s NDA is under review in the United States and EU. Acorda boasts a strong pipeline addressing a wide range of disorders. The restructing initiative is also encuraging. The company’s share price has outperformed the industry so far this year. However, the company’s key multiple sclerosis drug Ampyra is expected to face generic competition from mid-2018 in the United States. Hence, Acorda’s dependence on Ampyra to draw major part of its revenues is concerning. Moreover, Inbrija received a refusal-to-file letter from the FDA for NDA for Inbrija last August. This in turn delayed its expected commercial launch, which was anticipated much earlier." (7/3/2018)
Has Acorda Therapeutics been receiving favorable news coverage?
News headlines about ACOR stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Acorda Therapeutics earned a coverage optimism score of -1.4 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future.
Who are some of Acorda Therapeutics' key competitors?
Some companies that are related to Acorda Therapeutics include China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), Atara Biotherapeutics (ATRA), Regenxbio (RGNX), Editas Medicine (EDIT), Autolus Therapeutics (AUTL), Momenta Pharmaceuticals (MNTA), Sangamo Therapeutics (SGMO) and Iovance Biotherapeutics (IOVA).
Who are Acorda Therapeutics' key executives?
Acorda Therapeutics' management team includes the folowing people:
- Dr. Ron Cohen, Founder, CEO, Pres & Director (Age 63)
- Mr. David Lawrence, Chief Technology officer, Chief of Bus. Operations & Principal Accounting Officer (Age 61)
- Ms. Lauren M. Sabella, Chief Commercial Officer (Age 58)
- Mr. Andrew Asa Hindman, Chief Bus. Officer (Age 46)
- Dr. Burkhard Blank, Chief Medical Officer (Age 64)
Who are Acorda Therapeutics' major shareholders?
Acorda Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Bowling Portfolio Management LLC (0.18%), Louisiana State Employees Retirement System (0.03%) and Meeder Asset Management Inc. (0.03%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Barry E Greene, Burkhard Blank, David Lawrence, Ian F Smith, Lauren M Sabella, Lorin Randall, Ron Cohen, Scopia Capital Management Lp and Steven M Rauscher. View Institutional Ownership Trends for Acorda Therapeutics.
Which major investors are selling Acorda Therapeutics stock?
ACOR stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System. Company insiders that have sold Acorda Therapeutics company stock in the last year include Andrew A Hindman, Burkhard Blank, David Lawrence, Ian F Smith, Lauren M Sabella, Lorin Randall, Ron Cohen, Scopia Capital Management Lp and Steven M Rauscher. View Insider Buying and Selling for Acorda Therapeutics.
Which major investors are buying Acorda Therapeutics stock?
ACOR stock was bought by a variety of institutional investors in the last quarter, including Bowling Portfolio Management LLC and Meeder Asset Management Inc.. Company insiders that have bought Acorda Therapeutics stock in the last two years include Ron Cohen and Scopia Capital Management Lp. View Insider Buying and Selling for Acorda Therapeutics.
How do I buy shares of Acorda Therapeutics?
Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acorda Therapeutics' stock price today?
One share of ACOR stock can currently be purchased for approximately $16.26.
How big of a company is Acorda Therapeutics?
Acorda Therapeutics has a market capitalization of $773.29 million and generates $588.29 million in revenue each year. The biopharmaceutical company earns $-223,350,000.00 in net income (profit) each year or $1.04 on an earnings per share basis. Acorda Therapeutics employs 484 workers across the globe.
What is Acorda Therapeutics' official website?
How can I contact Acorda Therapeutics?
Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300.
MarketBeat Community Rating for Acorda Therapeutics (NASDAQ ACOR)
MarketBeat's community ratings are surveys of what our community members think about Acorda Therapeutics and other stocks. Vote "Outperform" if you believe ACOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
